Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

Pituitary

Volumn 14, Issue 1, 2011, Pages 80-91

  Dillard, Troy H ^a   Gultekin, S Humayun ^a   Delashaw Jr , Johnny B ^a   Yedinak, Chris G ^a   Neuwelt, Edward A ^b   Fleseriu, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Corticotroph adenoma; Cushing's disease; Pituitary adenoma; Pituitary tumor; Temozolomide

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; KI 67 ANTIGEN; TEMOZOLOMIDE;

ADULT; ARTICLE; CASE REPORT; CRANIOTOMY; DRUG DOSE TITRATION; HUMAN; HYPERCORTISOLISM; HYPOPHYSIS ADENOMA; INTENSITY MODULATED RADIATION THERAPY; MALE; NAUSEA; OPHTHALMOPLEGIA; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ACTH-SECRETING PITUITARY ADENOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; HUMANS; MALE; MIDDLE AGED; OPHTHALMOPLEGIA; PITUITARY NEOPLASMS;

EID: 79951958105     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-010-0264-1     Document Type: Article

References (54)

1. G Assié H Bahurel J Coste S Silvera M Kujas M-A Dugué F Karray B Dousset J Bertherat P Legmann X Bertagna 2007 Corticotroph tumor progression after adrenalectomy in Cushing's Disease: a reappraisal of Nelson's Syndrome J Clin Endocrinol Metab 92 172 179 10.1210/jc.2006-1328 17062771 (Pubitemid 46067527)
2. LS Blevins N Sanai S Kunwar JK Devin 2009 An approach to the management of patients with residual Cushing's disease J Neuro-Oncol 94 313 319 1:CAS:528:DC%2BD1MXhtVegsLrJ 10.1007/s11060-009-9888-2
3. MS Bobola DD Kolstoe A Blank JR Silber 2010 Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression Mol Cancer Ther 9 1208 1218 1:CAS:528:DC%2BC3cXlsleksbw%3D 10.1158/1535-7163.MCT-10-0010 20457618
4. MS Bobola JR Silber RG Ellenbogen JR Geyer A Blank RD Goff 2005 O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines Clin Cancer Res 11 2747 2755 1:CAS:528:DC%2BD2MXivFKisLY%3D 10.1158/1078-0432.CCR-04-2045 15814657 (Pubitemid 40569477)
5. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C (2010) SOM230 (Pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes, 2010 May 21 [Epub ahead of print]
6. GN Burrow G Wortzman NB Rewcastle RC Holgate K Kovacs 1981 Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series N Engl J Med 304 156 158 1:STN:280:DyaL3M%2FnsVylsA%3D%3D 10.1056/ NEJM198101153040306 7442734 (Pubitemid 11163000)
7. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Jr., Vance ML, Thorner MO, Laws ER, Jr., Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab, 2010 Jul 28 [Epub ahead of print]
8. S Byrne C Karapetis N Vrodos 2009 A novel use of temozolomide in a patient with malignant prolactinoma J Clin Neurosci 16 1694 1696 10.1016/j.jocn.2009.05.013 19818629
9. AF Daly M Rixhon C Adam A Dempegioti MA Tichomirowa A Beckers 2006 High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege Belgium J Clin Endocrinol Metab 91 4769 4775 1:CAS:528:DC%2BD28XhtlGru77F 10.1210/jc.2006-1668 (Pubitemid 44917305)
10. C de Bruin AM Pereira RA Feelders JA Romijn F Roelfsema DM Sprij-Mooij MO van Aken A-J van der Lelij WW de Herder SWJ Lamberts LJ Hofland 2009 Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas J Clin Endocrinol Metab 94 1118 1124 10.1210/jc.2008-2101 19141584
11. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents New England J Med 343 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 10.1056/NEJM200011093431901
12. M Esteller SR Hamilton PC Burger SB Baylin JG Herman 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 1:CAS:528:DyaK1MXht1Sjurk%3D 10029064 (Pubitemid 29086728)
13. J Estrada M Boronat M Mielgo R Magallon I Millan S Diez T Lucas B Barcelo 1997 The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease New England J Med 336 172 177 1:STN:280:DyaK2s7jtFOgsA%3D%3D 10.1056/NEJM199701163360303 (Pubitemid 27034962)
14. CE Fadul AL Kominsky LP Meyer LS Kingman WB Kinlaw CH Rhodes CJ Eskey NE Simmons 2006 Long-term response of pituitary carcinoma to temozolomide Report Two Cases J Neurosurg 105 621 626 (Pubitemid 44525896)
15. RA Feelders C de Bruin AM Pereira JA Romijn RT Netea-Maier AR Hermus PM Zelissen R van Heerebeek FH de Jong A-J van der Lely WW de Herder LJ Hofland SW Lamberts 2010 Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease The New England J Med 362 1846 1848 1:CAS:528: DC%2BC3cXmtVahu7c%3D 10.1056/NEJMc1000094
16. M Fleseriu DL Loriaux WH Ludlam 2007 Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful current opinion in endocrinology Diabetes Obes 14 323 328 10.1097/MED.0b013e328248b498 (Pubitemid 47067119)
17. A Guzel M Tatli S Senturk E Guzel SR Cayli A Sav 2008 Pituitary carcinoma presenting with multiple metastases: case report J Child Neurol 23 1467 1471 10.1177/0883073808319078 19073854
18. C Hagen HD Schroeder S Hansen M Andersen 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy Eur J Endocrinol Eur Federation Endocrine Soc 161 631 637 1:CAS:528:DC%2BD1MXhtlOit7nN
19. WA Hall MG Luciano JL Doppman NJ Patronas EH Oldfield 1994 Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population Ann Intern Med 120 817 820 1:STN:280:DyaK2c3gsFOltg%3D%3D 8154641 (Pubitemid 24140506)
20. ME Hegi A-C Diserens S Godard P-Y Dietrich L Regli S Ostermann P Otten G Van Melle N de Tribolet R Stupp 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res Official J Am Assoc Cancer Res 10 1871 1874 1:CAS:528:DC%2BD2cXisVGltbY%3D (Pubitemid 38375541)
21. GA Kaltsas P Nomikos G Kontogeorgos M Buchfelder AB Grossman 2005 Diagnosis and management of pituitary carcinomas J Clin Endocrinol Metab 90 3089 3099 1:CAS:528:DC%2BD2MXkt1Wgu78%3D 10.1210/jc.2004-2231 15741248 (Pubitemid 40686369)
22. E Knosp E Steiner K Kitz C Matula 1993 Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings Neurosurgery 33 610 617 1:STN:280: DyaK2c%2FltVCnsQ%3D%3D 10.1227/00006123-199310000-00008 8232800 discussion 617-618
23. K Kovacs E Horvath LV Syro H Uribe LC Penagos LD Ortiz CE Fadul 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings Hum Pathol 38 185 189 1:CAS:528: DC%2BD28XhtleisrfE 10.1016/j.humpath.2006.07.014 17056093 (Pubitemid 44880216)
24. K Kovacs B Scheithauer M Lombardero R McLendon L Syro H Uribe L Ortiz L Penagos 2008 MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy Acta Neuropathol 115 261 262 10.1007/s00401-007-0279-5 17926052
25. H Kurzen S Schmitt H Näher T Möhler 2003 Inhibition of angiogenesis by non-toxic doses of temozolomide Anti-Cancer Drugs 14 515 522 1:CAS:528:DC%2BD3sXmvF2itr0%3D 10.1097/00001813-200308000-00003 12960735 (Pubitemid 37083156)
26. S Lim H Shahinian MM Maya W Yong AP Heaney 2006 Temozolomide: a novel treatment for pituitary carcinoma Lancet Oncol 7 518 520 10.1016/S1470-2045(06) 70728-8 16750503 (Pubitemid 43796152)
27. JK Liu M Fleseriu IS Ciric J Delashaw B Johnny WT Couldwell 2007 Treatment options for Cushing disease after unsuccessful transsphenoidal surgery Neurosurg Focus 23 E8 10.3171/foc.2007.23.3.10 17961031
28. Lloyd R, Kovacs K, Young W Jr, Farrel W, Asa S, Truillas J, Kontogeorgos G, Sano T, Scheithauer B, Horvath E, DeLellis R, Heitz P (2004) Pituitary tumors. In: DeLellis R et al (eds) WHO classification of tumors of the endocrine organs: Pathology and genetics of endocrine organs. IARC Press, Lyon, pp 10-13
29. JC Maiza P Caron 2009 Carcinomes et adenomes hypophysaires agressifs : mise au point et nouvelles options therapeutiques Ann Endocrinol (Paris) 70 Suppl 1 S12 S19 1:CAS:528:DC%2BD1MXhtlKrs7vK
30. 6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours Clin Endocrinol 71 226 233 1:CAS:528:DC%2BD1MXhtVSqt7bJ 10.1111/j.1365-2265.2008.03487.x
31. S Mohammed MD Cusimano BW Scheithauer F Rotondo E Horvath K Kovacs 2010 O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma Neurosurgery 66 E421 E422 10.1227/01.NEU.0000363852.77126.AD 20087113
32. S Mohammed K Kovacs W Mason H Smyth MD Cusimano 2009 Use of temozolomide in aggressive pituitary tumors: case report Neurosurgery 64 E773 E774 10.1227/01.NEU.0000339115.12803.4E 19349807 discussion E774
33. Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O (2010) Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 1-4
34. VJ Moyes G Alusi HI Sabin J Evanson DM Berney K Kovacs JP Monson PN Plowman WM Drake 2009 Treatment of Nelson's syndrome with temozolomide Eur J Endocrinol 160 115 119 1:CAS:528:DC%2BD1MXhsVOhsb%2FJ 10.1530/EJE-08-0557 18984772
35. EA Natelson D Pyatt 2010 Temozolomide-induced myelodysplasia Adv Hematol 2010 760402 20224797
36. LM Neff M Weil A Cole TR Hedges W Shucart D Lawrence J-J Zhu AS Tischler RM Lechan 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists Pituitary 10 81 86 10.1007/s11102-007-0014-1 17285366 (Pubitemid 46562811)
37. PJ Pernicone BW Scheithauer TJ Sebo KT Kovacs E Horvath WF Young Jr RV Lloyd DH Davis BL Guthrie WC Schoene 1997 Pituitary carcinoma: a clinicopathologic study of 15 cases Cancer 79 804 812 1:STN:280: DyaK2s7nslWltQ%3D%3D 10.1002/(SICI)1097-0142(19970215)79:4<804::AID- CNCR18>3.0.CO;2-3 9024719 (Pubitemid 27076347)
38. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon A Walker HS Friedman 2009 Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol Official J Am Soc Clin Oncol 27 1262 1267 1:CAS:528:DC%2BD1MXktFKhsLY%3D
39. Z Ram LK Nieman GB Cutler Jr GP Chrousos JL Doppman EH Oldfield 1994 Early repeat surgery for persistent Cushing's disease J Neurosurg 80 37 45 1:STN:280:DyaK2c%2Fps1Witw%3D%3D 10.3171/jns.1994.80.1.0037 8271020 (Pubitemid 24020703)
40. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia J-G, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a french multicenter experience. J Clin Endocrinol Metab. doi: 10.1210/jc.2010-0644
41. A Saveanu G Gunz S Guillen H Dufour MD Culler P Jaquet 2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas Neuroendocrinology 83 258 263 1:CAS:528:DC%2BD28XhtV2hu7vE 10.1159/000095536 17047391 (Pubitemid 44578880)
42. A Saveanu P Jaquet T Brue A Barlier 2008 Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas Mol Cell Endocrinol 286 206 213 1:CAS:528:DC%2BD1cXmtVSmtL4%3D 10.1016/j.mce.2007.12.008 18241980
43. A Shaikh N Masood 2010 Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report J Med Case Reports 4 274 10.1186/1752-1947-4-274 20718954
44. JM Sheehan ML Vance JP Sheehan DB Ellegala ER Laws 2000 Radiosurgery for Cushing's disease after failed transsphenoidal surgery J Neurosurg 93 738 742 1:STN:280:DC%2BD3crgslyhsg%3D%3D 10.3171/jns.2000.93.5.0738 11059652 (Pubitemid 32803394)
45. RM Starke BJ Williams ML Vance JP Sheehan 2010 Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review Curr Opin Endocrinol Diabetes Obes 17 356 364 10.1097/MED.0b013e32833ab069 20531182
46. R Stupp PY Dietrich S Ostermann Kraljevic A Pica I Maillard P Maeder R Meuli R Janzer G Pizzolato R Miralbell F Porchet L Regli N de Tribolet RO Mirimanoff S Leyvraz 2002 Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375 1382 1:CAS:528: DC%2BD38XisVWmu7s%3D 10.1200/JCO.20.5.1375 11870182 (Pubitemid 34177445)
47. LV Syro BW Scheithauer LD Ortiz CE Fadul E Horvath F Rotondo K Kovacs 2009 Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma Hormones (Athens, Greece) 8 303 306
48. LV Syro H Uribe LC Penagos LD Ortiz CE Fadul E Horvath K Kovacs 2006 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm Clin Endocrinol 65 552 553 10.1111/j.1365-2265.2006.02653.x (Pubitemid 44414285)
49. A Takeshita N Inoshita M Taguchi C Okuda N Fukuhara K Oyama K Ohashi T Sano Y Takeuchi S Yamada 2009 High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease European J Endocrinol Eur Federation Endocrine Soc 161 553 559 1:CAS:528:DC%2BD1MXhtlOit7jN
50. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL (2009) Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary 1-7. doi: 10.1007/s11102-009-0211-1
51. SR Wedge JK Porteous ES Newlands 1997 Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model Cancer Chemother Pharmacol 40 266 272 1:CAS:528:DyaK2sXjvF2kurc%3D 10.1007/s002800050657 9219512 (Pubitemid 27258665)
52. SR Wedge JK Porteus BL May ES Newlands 1996 Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro Br J Cancer 73 482 490 1:CAS:528:DyaK28Xhs1Kjtrg%3D 10.1038/bjc.1996.85 8595163 (Pubitemid 26056467)
53. G Widhalm S Wolfsberger M Preusser A Woehrer MR Kotter T Czech C Marosi E Knosp 2009 O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115 1070 1080 1:CAS:528:DC%2BD1MXjs1Kju7o%3D 10.1002/cncr.24053 19156926
54. Yildiz F. Zorlu F. Erbas T. Atahan L. Radiotherapy in the management of giant pituitary adenomas Radiotherapy and Oncology 1999 52 3 233-237 (Pubitemid 29486642)